Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06326684 · ClinicalTrials.gov registry record · Early Phase 1

Suvorexant and Alcohol

A Early Phase 1 study of Alcohol Use Disorder, sponsored by William Stoops.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06326684: Recruiting Early Phase 1 study of Alcohol Use Disorder, sponsored by William Stoops.

NCT06326684 is a Early Phase 1 study of Alcohol Use Disorder that is actively recruiting participants, run by William Stoops. The registered enrollment target is 30 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06326684, a Early Phase 1 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by William Stoops.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.

Primary Outcome

Number of Times Subjects Choose Alcohol (Maximum of 5 Choices) Over Money

Conditions Studied

Alcohol Use Disorder

Interventions

  • DRUG Placebo
  • DRUG Alcohol
  • DRUG Suvorexant

Study Locations (1)

Kentucky

  • Psychopharmacology of Addiction Laboratory - Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-06-07
Est. Completion 2027-03-15
Phase Early Phase 1
William Stoops

13 total trials

What NCT06326684 shows while recruiting

NCT06326684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06326684 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT06326684 about?

NCT06326684 is a clinical study titled "Suvorexant and Alcohol". This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science i...

What is the current status of trial NCT06326684?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2024-06-07. Estimated completion is 2027-03-15.

What conditions does trial NCT06326684 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT06326684?

The interventions under investigation include: Placebo (DRUG), Alcohol (DRUG), Suvorexant (DRUG).

Who is sponsoring clinical trial NCT06326684?

This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06326684 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06326684's enrollment target sits among peer trials

30 151st of 184 higher than 26 of 184 other Alcohol Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06326684

Source: ClinicalTrials.gov NCT06326684, the US trial registry maintained by the National Library of Medicine. NCT06326684 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.